147526-32-7 C50H46CaF2N2O8 Pitavastatin calcium CAS NO.147526-32-7

pitavastatin calcium basic information

statin lipid-lowering drugs pharmacological effects pharmacokinetics toxicity clinical study

product name:	pitavastatin calcium
synonyms:	6-heptenoicacid,7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl)-3,5-dihydro;calciumsalt(2:1),(3r,5s,6e)-xy;nk104;nk104(acid);itavastatin ca;itavastatin calcium;pitavastatin calcium;：(+)-monocalciumbis{(3r,5s,6e)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}
cas:	147526-32-7
mf:	c50h46caf2n2o8
mw:	880.98
einecs:
product categories:	active pharmaceutical ingredients;inhibitors;intermediates & fine chemicals;pharmaceuticals;chemical;api;livalo
mol file:	147526-32-7.mol

pitavastatin calcium chemical properties

cas database reference

147526-32-7(cas database reference)

safety information

msds information

pitavastatin calcium usage and synthesis

statin lipid-lowering drugs	pitavastatin calcium is jointly developed by two companies nissan chemical and kowa co.it is the first total synthesis hmg-coa reductase inhibitor, it belongs to statin drugs ,it reduces the ability of the liver to manufacture cholesterol mainly through inhibition of some liver enzymes called hmgco-a reductase , thus it improves the elevated blood cholesterol levels, it is primarily used for the treatment of hypercholesterolemia and familial hypercholesterolemia patients,its lipid-lowering effect is very good, it is the most potent lipid-lowering drug so far.
pharmacological effects	inhibition of hmg-coa reductase: pitavastatin calcium has a strongly antagonistic inhibition effect on hmg-coa enzyme , ic50 value is 6.8 nmol / l, and its intensity is 24 times of simvastatin, while it is 68 times of fluvastatin. it hinders the synthesis of cholesterol: the ability to effectively inhibit the process of generating cholesterol in human hepatocytes hepg2 , ic50 value is 5.8nmol / l, and its intensity is 29 times of simvastatin, it is 57 times that of atorvastatin. but pitavastatin calcium inhibition effect on each enzyme in cholesterol generation after generation of mevalonate is very weak. it increases ldl receptor density: pitavastatin induces the synthesis of lds receptor mrna in the ultra-low concentration of 1μmol / l, it can increase the number of lds receptor mrna , it results in the increasing of ldl receptor density , thereby it promotes clearance of ldl , so that plasma ldl - plasma total cholesterol concentration and triglyceride concentration decrease. the above information is edited by the chemicalbook of tian ye.
pharmacokinetics	the main parts of its absorption after oral administration are the duodenum and colon,its rate of binding plasma protein in the body is 96%and it is more selectively distributed in the liver after absorption , the drug concentration in body tissues is lower than that in the plasma or the same as that in the plasma . pitavastatin calcium is mainly metabolized in the liver, kidney, lung, heart, muscle , metabolite concentrations are lower than the concentration of drug prototype, it is excreted through feces,there is also a small amount of drug excretion through urine , total excretion rate is almost 100%. a healthy male adult oral pitavastatin is 0.5 ~ 8mg, t1 / 2 is about 10h,the cmax and auc of the prototype drug in plasma increase with increasing dose , repeatedly taking does not result in medication savings.
toxicity	acute toxicity: rats and dogs oral,study its acute toxicity. pitavastatin calcium median lethal dose on the rats are about male 500 ~ 1000mg / kg, female 250 ~ 500 mg / kg, dogs lethal dose is about 50 ~ 100mg / kg. long term toxicity: respectively, rats, dogs and monkeys are administered a long-term experiment. from the experimental results, the safe dose of pitavastatin calcium are rats 1 mg / kg · d-1 (6 months), canine 0.3mg / kg · d-1 (12 months), monkey 3mg / kg · d-1 (6 months). no central nervous system, reproductive system, and myocardial dysfunction is observed which is common while taking other statins during administration. carcinogenicity, mutagenicity: mouse oral 1,12,30, 75mg / kg dose, the incidence of cancer has no significant increase than in the control group .in chromosome abnormality tests, at the highest concentration of 625μg / ml,the result is positive, but at the same concentration, gene mutation recovery tests, micronucleus test s(in vivo) and uds test s(in vivo) are negative.
clinical study	in the therapeutic effect, statins is the first in the lipid-lowering drugs in which pitavastatin effect is very obvious, pitavastatin calcium is a third generation statins anti-hyperlipidemia drug, and russell atorvastatin (rosuvastatin ) while being called "super statin", is one of the better statins which are current international clinical application of the treatment of hypercholesterolemia, familial hypercholesterolemia , because its clinically effective dose is 1-2mg / day, significantly lower than other marketed statins, with high efficiency, and security features, it has a good tolerability. clinical trail phase i results show that pitavastatin calcium in 1,2,4 mg dose has clinical significance in patients with high blood cholesterol. results of clinical trail phase ⅱ determine that the best dosage of the pitavastatin calcium for the treatment of hyperlipidemia is 2mg / d. clinical trail phaseⅲ comparison of experimental results show that the efficacy of pitavastatin calcium on reducing tc and ldl-c is better than the effect of fluvastatin, and there is no significant difference in safety. multi-center long-term administration tests carried out in japan show that the dosage in 1 ~ 4mg / d range can effectively control blood lipid levels. the above test results demonstrate the effectiveness of pitavastatin calcium in treatment of hyperlipidemia on clinic.
chemical properties	white to off-white powder
usage	a competitive inhibitor of hmg-coa reductase.
usage	pitavastatin calcium (livalo) is a novel member of the medication class of statins

pitavastatin calcium preparation products and raw materials

hennan sunlake enterprise corporation is located in henan province , the central plain of china , which enjoys favorable geogeaphical position and convenient transportion, the com[any was established in june. 1998 , until now having more than 18 years experience in manufacturing & exporting chemical raw material .

sunlake is a professional manufacturer engaged in producing and selling chemicals,including organic & inorganic chemicals , pigments & dyestuffs , water treatment chemicals , food & feed additives and others . these products have been being well exported to europe , southeast asia , the middle east , africa , south america and some other countries and areas.

we sincerely welcome foreign friends to visit our plant for cooperation. with the idea of "quality first,credit priority, excellent service", we are highly acknowledged by customers for good quality and competitive price. more importantly , the company has a strong r & d team, who are professional engineers and scholars with ph. d. .so we are confident to serve you better with our high - quality products and professional team.

we are taking great efforts to provide our customers with demanded goods and professional services, and continuously improve our core ability of competition and get the momentum for sustainable development, and finally make us being a reliable and professional wupplier in international market. we welcome any serious inquiries from all customers of the world, and sincerely hope to cooperate with you for a brilliant future!